Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group

Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group

ACIP General Meeting
February 23, 2023



Work group members

ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

Kevin Ault (Western Michigan University)

Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O'Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Mila Prill

Natalie Thornburg

Aron Hall

Ismael Ortega-Sanchez

Tamara Pilishvili

Melissa Coughlin

Jamison Pike

Lauren Roper

Amber Winn

Chris Taylor

Claire Midgley

Fiona Havers

Tami Skoff

Angie Campbell

Michael Melgar

Amanda Payne

Nicole Dowling

Noelle Molinari

Pragna Patel

Andrea Sharma

GRADE/EtR consultants

Doug Campos-Outcalt

Rebecca Morgan

Previous maternal/pediatric RSV ACIP presentations

- Epidemiology and burden of RSV in infants
  - RSV seasonality in United States
  - Outpatient, emergency department (ED) visits, hospitalizations, and deaths
- Virology and immunology of RSV
- Safety and efficacy of nirsevimab
  - Phase 3 study in infants born ≥35 weeks gestation (initial and updated results)[1]
  - Phase 2b study in infants born 29–34 weeks gestation
  - Phase 2/3 safety and pharmacokinetic study in infants at high risk of RSV disease[2]

[1]Initial results from start of trial until pause for COVID-19 pandemic and updated results that included entire sample. [2]Eligible for palivizumab.

Agenda: Thursday February 23, 2023

Cost effectiveness analysis for nirsevimab – CDC model	Dr. David Hutton (University of Michigan)
Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model	Dr. Ismael Ortega Sanchez (CDC)
Evidence to Recommendations framework for nirsevimab	Dr. Jefferson Jones (CDC)
Clinical considerations for nirsevimab	Dr. Jefferson Jones (CDC)
Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine	Dr. Iona Munjal (Pfizer)
Workgroup considerations	Dr. Katherine Fleming-Dutra (CDC)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov